In Vitro Dissolution and In Vivo Bioavailability of Six Brands of Ciprofloxacin Tablets Administered in Rabbits and Their Pharmacokinetic Modeling

Table 2

Noncompartmental analysis of ciprofloxacin from the tested products and the reference products after oral administration in rabbit.

Parameter	A	B	C	D	E	F
𝑇max (hr)	1±0	1±0	1.5±0	1±0	1±0	1±0
𝐶max (mg/L)	11±0.12	10.83±0.13	9.73±0.16	11.64±0.11	10.87±0.11	10.35±0.13
AUC last (hr·mg/L)	47.99±0.35	40.04±0.52^∗	44.23±0.72	44.44±0.62	47.97±0.22	45.763±0.49
Lambda_z (1/hr)	0.23±0.01	0.23±0.008	0.23±0.015	0.23±0.01	0.21±0.01	0.177±0.01
HL_Lambda_z (hr)	3.001±0.19	2.99±0.19	3.02±0.195	3.00±0.18	3.33±0.17	4.17±0.20
AUC INF_obs (hr·mg/L)	57.45±2.07	47.42±1.95^∗	53.46±2.10	52.89±1.54	59.58±1.14	62.24±1.98
Vz_F_obs (L)	37.67±1.02	45.51±0.95	40.76±1.072	40.96±1.24	40.31±1.34	48.32±0.89
Cl_F_obs (L/hr)	8.703±0.21	10.54±0.25	9.36±0.37	9.45±0.24	8.39±0.16	8.04±0.26
AUMClast (hr·hr·mg/L)	138.02±3.12	109.93±3.29^∗	130.55±4.62	124.23±3.65	140.69±1.36	140.03±3.25
MRT last (hr)	2.87±0.04	2.74±0.03	2.95±0.06	2.79±0.04	2.93±0.03	3.06±0.04

^∗𝑃<0.05.